The expression of p38, ERK1 and Bax proteins has increased during the treatment of newly diagnosed acute promyelocytic leukemia with arsenic trioxide

Annals of Oncology

Volumn 21, Issue 9, 2010, Pages 1884-1890

  Mandegary, A ^a,b   Hosseini, R ^a   Ghaffari, S H ^c   Alimoghaddam, K ^c,d   Rostami, S ^c   Ghavamzadeh, A ^c   Ghahremani, M H ^a,d  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Acute promyelocytic leukemia; Arsenic trioxide; Bax; ERK; p38

Indexed keywords

ARSENIC TRIOXIDE; CASPASE 3; DEXAMETHASONE; IDARUBICIN; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN BAX; RETINOIC ACID;

ACUTE KIDNEY FAILURE; ADOLESCENT; ADULT; AGITATION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; ANXIETY; APOPTOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLURRED VISION; BONE MARROW BIOPSY; BONE PAIN; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; DRY SKIN; DYSPNEA; EDEMA; ENZYME ACTIVITY; ERYTHEMA; EYE IRRITATION; FACE EDEMA; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERKALEMIA; HYPERPIGMENTATION; INSOMNIA; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LEUKOCYTOSIS; MALE; MUSCULOSKELETAL PAIN; NAUSEA AND VOMITING; NIGHT SWEAT; PARESTHESIA; PLEURA EFFUSION; PRIORITY JOURNAL; PROMYELOCYTE; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; PROTEIN FUNCTION; QT PROLONGATION; RESPIRATORY DISTRESS; SIDE EFFECT; THORAX PAIN; TREMOR; WEAKNESS; WEIGHT GAIN;

EID: 77956127094     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq034     Document Type: Article

References (35)

1. Warrell RP Jr, Frankel SR, Miller WH Jr. et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 1991; 324: 1385-1393.
2. Bode AM, Dong Z. The paradox of arsenic: molecular mechanisms of cell transformation and chemotherapeutic effects. Crit Rev Oncol Hematol 2002; 42: 5-24.
3. Chou WC, Dang CV. Acute promyelocytic leukemia: recent advances in therapy and molecular basis of response to arsenic therapies. Curr Opin Hematol 2005; 12: 1-6.
4. Zheng Y, Yamaguchi H, Tian C et al. Arsenic trioxide (As(2)O(3)) induces apoptosis through activation of Bax in hematopoietic cells. Oncogene 2005; 24: 3339-3347.
5. Nutt LK, Gogvadze V, Uthaisang W et al. Indirect effects of Bax and Bak initiate the mitochondrial alterations that lead to cytochrome c release during arsenic trioxide-induced apoptosis. Cancer Biol Ther 2005; 4: 459-467.
6. Kinjo K, Kizaki M, Muto A et al. Arsenic trioxide (As2O3)-induced apoptosis and differentiation in retinoic acid-resistant acute promyelocytic leukemia model in hGM-CSF-producing transgenic SCID mice. Leukemia 2000; 14: 431-438.
7. Reed JC. Bcl-2 family proteins: regulators of chemoresistance in cancer. Toxicol Lett 1995; 82-83: 155-158.
8. Roth W, Reed JC. Apoptosis and cancer: when BAX is TRAILing away. Nat Med 2002; 8: 216-218.
9. Platanias LC. Map kinase signaling pathways and hematologic malignancies. Blood 2003; 101: 4667-4679.
10. Miranda MB, McGuire TF, Johnson DE. Importance of MEK-1/-2 signaling in monocytic and granulocytic differentiation of myeloid cell lines. Leukemia 2002; 16: 683-692.
11. Yen A, Roberson MS, Varvayanis S, Lee AT. Retinoic acid induced mitogenactivated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase-dependent MAP kinase activation needed to elicit HL-60 cell differentiation and growth arrest. Cancer Res 1998; 58: 3163-3172.
12. Alsayed Y, Uddin S, Mahmud N et al. Activation of Rac1 and the p38 mitogenactivated protein kinase pathway in response to all-trans-retinoic acid. J Biol Chem 2001; 276: 4012-4019.
13. Verma A, Mohindru M, Deb DK et al. Activation of Rac1 and the p38 mitogenactivated protein kinase pathway in response to arsenic trioxide. J Biol Chem 2002; 277: 44988-44995.
14. Soignet SL, Maslak P, Wang ZG et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998; 339: 1341-1348.
15. Alimoghaddam K, Shariftabrizi A, Tavangar SM et al. Anti-leukemic and antiangiogenesis efficacy of arsenic trioxide in new cases of acute promyelocytic leukemia. Leuk Lymphoma 2006; 47: 81-88.
16. Ghavamzadeh A, Alimoghaddam K, Ghaffari SH et al. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol 2006; 17: 131-134.
17. Cowland JB, Borregaard N. Isolation of neutrophil precursors from bone marrow for biochemical and transcriptional analysis. J Immunol Methods 1999; 232: 191-200.
18. Raffoux E, Rousselot P, Poupon J et al. Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia. J Clin Oncol 2003; 21: 2326-2334.
19. Shen ZX, Shi ZZ, Fang J et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A 2004; 101: 5328-5335.
20. Zheng X, Seshire A, Ruster B et al. Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells. Haematologica 2007; 92: 323-331.
21. Niu C, Yan H, Yu T et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999; 94: 3315-3324.
22. Ravandi F, Estey E, Jones D et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol 2009; 27: 504-510.
23. Ghavamzadeh A, Alimoghaddam K, Ghaffari SH et al. Treatment of new cases of acute promyelocytic leukemia by arsenic trioxide without ATRA +/- chemotherapy and long term follow up of patients. Blood 2008; 112: (ASH Annual Meeting) (Abstr140).
24. Cai X, Shen YL, Zhu Q et al. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia 2000; 14: 262-270.
25. Chen GQ, Zhu J, Shi XG et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 1996; 88: 1052-1061.
26. Puccetti E, Beissert T, Guller S et al. Leukemia-associated translocation products able to activate RAS modify PML and render cells sensitive to arsenic-induced apoptosis. Oncogene 2003; 22: 6900-6908.
27. Hossain K, Akhand AA, Kato M et al. Arsenite induces apoptosis of murine T lymphocytes through membrane raft-linked signaling for activation of c-Jun amino-terminal kinase. J Immunol 2000; 165: 4290-4297.
28. Hu X, Moscinski LC, Valkov NI et al. Prolonged activation of the mitogenactivated protein kinase pathway is required for macrophage-like differentiation of a human myeloid leukemic cell line. Cell Growth Differ 2000; 11: 191-200.
29. Racke FK, Lewandowska K, Goueli S, Goldfarb AN. Sustained activation of the extracellular signal-regulated kinase/mitogen-activated protein kinase pathway is required for megakaryocytic differentiation of K562 cells. J Biol Chem 1997; 272: 23366-23370.
30. Moosavi MA, Yazdanparast R. Distinct MAPK signaling pathways, p21 upregulation and caspase-mediated p21 cleavage establishes the fate of U937 cells exposed to 3-hydrogenkwadaphnin: differentiation versus apoptosis. Toxicol Appl Pharmacol 2008; 230: 86-96.
31. Han B, Wei W, Hua F et al. Requirement for ERK activity in sodium seleniteinduced apoptosis of acute promyelocytic leukemia-derived NB4 cells. J Biochem Mol Biol 2007; 40: 196-204.
32. Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 2001; 81: 807-869.
33. Matsuzawa A, Ichijo H. Redox control of cell fate by MAP kinase: physiological roles of ASK1-MAP kinase pathway in stress signaling. Biochim Biophys Acta 2008; 1780: 1325-1336.
34. Schwerk C, Schulze-Osthoff K. Non-apoptotic functions of caspases in cellular proliferation and differentiation. Biochem Pharmacol 2003; 66: 1453-1458.
35. Sordet O, Rebe C, Plenchette S et al. Specific involvement of caspases in the differentiation of monocytes into macrophages. Blood 2002; 100: 4446-4453.